Profile data is unavailable for this security.
About the company
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
- Revenue in USD (TTM)37.89m
- Net income in USD-12.13m
- Incorporated2017
- Employees44.00
- LocationEquillium Inc2223 Avenida de La Playa Ste 105LA JOLLA 92037-3217United StatesUSA
- Phone+1 (858) 412-5302
- Fax+1 (302) 636-5454
- Websitehttps://www.equilliumbio.com/home/default.aspx
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Correlate Energy Corp | 7.56m | -12.79m | 50.55m | 19.00 | -- | -- | -- | 6.68 | -0.3554 | -0.3554 | 0.21 | -0.0877 | 2.22 | -- | 13.19 | 398,051.60 | -375.16 | -315.47 | -- | -- | 18.27 | 15.42 | -169.09 | -201.03 | -- | -0.7239 | 8.30 | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -39.26m | 52.21m | 15.00 | -- | 9.13 | -- | -- | -1.66 | -1.66 | 0.00 | 0.2048 | 0.00 | -- | -- | 0.00 | -184.22 | -- | -507.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.92 | -- | -- | -- |
| Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 53.19m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
| Enzo Biochem Inc | 32.80m | -23.31m | 53.27m | 179.00 | -- | 0.7419 | -- | 1.62 | -0.4699 | 0.6708 | 0.6586 | 1.40 | 0.3738 | 1.61 | 4.10 | 183,257.00 | -26.56 | -12.21 | -39.50 | -15.79 | 42.17 | 37.09 | -71.07 | -18.76 | 2.89 | -- | 0.0476 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| Modular Medical Inc | 0.00 | -16.76m | 53.30m | 37.00 | -- | 9.53 | -- | -- | -0.9653 | -0.9653 | 0.00 | 0.1805 | 0.00 | -- | -- | 0.00 | -224.40 | -168.16 | -262.22 | -209.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.51 | -- | 154.53 | -- |
| Checkpoint Therapeutics Inc | 103.00k | -51.85m | 53.53m | 23.00 | -- | -- | -- | 519.70 | -2.93 | -2.93 | 0.0055 | -0.4703 | 0.011 | -- | -- | 4,478.26 | -555.46 | -142.43 | -- | -342.79 | -- | -- | -50,336.89 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Equillium Inc | 37.89m | -12.13m | 53.94m | 44.00 | -- | 2.56 | -- | 1.42 | -0.3476 | -0.3476 | 1.08 | 0.5983 | 0.6568 | -- | 8.95 | 861,227.30 | -21.02 | -46.81 | -39.66 | -57.36 | -- | -- | -32.01 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| Ikena Oncology Inc | 9.16m | -68.17m | 54.04m | 43.00 | -- | 0.3667 | -- | 5.90 | -1.63 | -1.63 | 0.2196 | 3.52 | 0.0503 | -- | -- | 213,046.50 | -37.42 | -29.72 | -41.48 | -34.62 | -- | -- | -744.09 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Intensity Therapeutics Inc | 0.00 | -11.86m | 54.84m | 5.00 | -- | 4.17 | -- | -- | -0.8653 | -0.8653 | 0.00 | 0.9601 | 0.00 | -- | -- | 0.00 | -110.62 | -- | -254.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Avrobio Inc | 0.00 | 30.31m | 55.20m | 13.00 | 1.78 | -- | 1.80 | -- | 0.6903 | 0.6903 | 0.00 | -- | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Cidara Therapeutics Inc | 63.91m | -22.93m | 55.47m | 69.00 | -- | -- | -- | 0.868 | -0.2528 | -0.2528 | 0.7136 | -0.0906 | 1.12 | -- | 5.79 | 926,159.40 | -40.05 | -65.23 | -804.74 | -154.37 | 45.03 | -- | -35.88 | -100.61 | 0.8122 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Moolec Science SA | 2.65m | -52.66m | 55.65m | 45.00 | -- | 5.49 | -- | 21.04 | -1.44 | -1.44 | 0.0766 | 0.2367 | -- | -- | -- | 58,780.00 | -- | -- | -- | -- | 2.92 | -- | -1,990.79 | -- | 0.2243 | -0.1889 | 0.2372 | -- | -- | -- | -1,044.02 | -- | -- | -- |
| Kezar Life Sciences Inc | 7.00m | -101.87m | 56.25m | 58.00 | -- | 0.2998 | -- | 8.04 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Aligos Therapeutics Inc | 13.79m | -99.59m | 57.04m | 66.00 | -- | -- | -- | 4.14 | -1.50 | -1.50 | 0.1783 | -- | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -9.00 | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
Data as of May 10 2024. Currency figures normalised to Equillium Inc's reporting currency: US Dollar USD
6.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 836.12k | 2.37% |
| Tang Capital Management LLCas of 31 Dec 2023 | 400.00k | 1.14% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 347.50k | 0.99% |
| Geode Capital Management LLCas of 31 Dec 2023 | 172.39k | 0.49% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 108.69k | 0.31% |
| Callan Capital LLCas of 31 Mar 2024 | 99.69k | 0.28% |
| PGIM Quantitative Solutions LLCas of 31 Dec 2023 | 65.40k | 0.19% |
| Citadel Securities LLCas of 31 Dec 2023 | 63.00k | 0.18% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 56.22k | 0.16% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 50.04k | 0.14% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
